The Australian company incorporated the subsidiary as it plans for the US launch of its ResistancePlus MG assay.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.
The subsidiary is being formed in support of Biocartis' recent US distribution deal with Thermo Fisher Scientific.
Jason Terrell will lead the subsidiary, which will be based in Austin, Texas.